{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-24-000038","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.186863+00:00","generated_at":"2026-05-30T07:51:47.625727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%","bullets":["Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).","Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.","Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).","FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.","FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-24-000038","json":"https://secwatch.observer/filing/0001804220-24-000038.json","markdown":"https://secwatch.observer/filing/0001804220-24-000038.md","text":"https://secwatch.observer/filing/0001804220-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/0001804220-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/regn-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:51:47.625727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}